Christopher Joncas, MD
Internal Medicine · Fall River, MANPI 1336136456
Payments from drug & device makers
Across 181 payments — averaging $459.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$82K
- Pfizer$251
- Merck$106
- Sunovion Pharmaceuticals Inc.$79
- Novo Nordisk$79
- AbbVie$52
- plus $499 from 19 others
What the payments were for
- Consulting fees$20,62525%
- Speaking & faculty fees$51,57162%
- Travel & lodging$5,7697%
- Food & beverage$5,1346%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 107 | $82,034 |
| Pfizer | 24 | $251 |
| Merck | 6 | $106 |
| Sunovion Pharmaceuticals Inc. | 12 | $79 |
| Novo Nordisk | 4 | $79 |
| AbbVie | 2 | $52 |
| Novartis | 2 | $46 |
| AstraZeneca | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Medtronic | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $20 |
| MDD US Operations, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$79,664
How this compares
$83,100 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 747 | $250,955 |
| JanuviaSitagliptin Phosphate | 263 | $147,449 |
| OzempicSemaglutide | 83 | $87,985 |
| JardianceEmpagliflozin | 148 | $78,059 |
| TrulicityDulaglutide | 58 | $74,234 |
| RybelsusSemaglutide | 47 | $56,970 |
| RexultiBrexpiprazole | 87 | $56,443 |
| MounjaroTirzepatide | 41 | $53,058 |
| TradjentaLinagliptin | 160 | $45,899 |
| XareltoRivaroxaban | 139 | $42,042 |
| RelistorMethylnaltrexone Bromide | 11 | $29,863 |
| FarxigaDapagliflozin Propanediol | 41 | $27,861 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 83 | $26,134 |
| MyrbetriqMirabegron | 70 | $24,988 |
| LinzessLinaclotide | 43 | $24,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $251 | $277,088830 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $79 | $154,986161 claims |
| MerckJanuvia | $106 | $147,449263 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $127,29299 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $40 | $56,44387 claims |
| AstraZenecaFarxiga, Lokelma | $43 | $42,56352 claims |
| Johnson & JohnsonXarelto | $18 | $42,042139 claims |
| AbbVieLinzess, Creon | $52 | $35,67863 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $22 | $32,42357 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $37 | $29,86311 claims |
| NovartisEntresto | $46 | $9,24625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Fall River
- Ehab SorialFall River$2.5M
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.